-

An application will be made to the Taiwan Rheumatology Association for accreditation, which will allow participants from Taiwan to claim CME points.

• Medical_Professionals
• Medical_students
• Exhibitors
• Press
• General_Public

We are most pleased to inform you that the 7th edition of the World Congress on Controversies, Debates & Consensus in Bone, Muscle & Joint Diseases (BMJD) will be held in Taipei, Taiwan from October 17 – 19, 2019, continuing its past successes in Thailand, Australia, Europe and North America.

BMJD has further enhanced the format of its program for 2019 with new approaches to yet more productive interactions and discussions between experts and participants, offering the best possible translational learning experience while sharing the most recent advances in the treatment and investigation of a number of musculoskeletal diseases.

The 2019 program will focus on the most challenging arthritic conditions seen in daily practice both in Asia and in the rest of the world. The aims will be to help physicians by improving the investigation and management of patients suffering from these diseases. Expert debates on the many advancements in the clinical and basic science fields of bone, muscle and joint diseases will focus on providing practical management solutions to challenging and clinically relevant issues encountered in daily practice.

In preparation for this Congress and to meet participant expectations, we are fortunate to be supported by a team of Asian and international renowned experts actively contributing to the scientific program.

We very much look forward to seeing you in Taipei and joining us for a unique and in-depth learning experience on the treatment of arthritic diseases.

Sincerely,

BMJD Chairpersons
Jean-Pierre Pelletier, Canada
Johanne Martel-Pelletier, Canada
Boulos Haraoui, Canada

Congress Chairpersons
Tore K. Kvien, Norway
Lee S. Simon, USA
Wen-Chan Tsai, Taiwan

• Gout and crystal arthropathies: Investigation and new treatments
• Is crystal arthropathy a local or systemic disease?
• Large vessel vasculitis: Is imaging truly helpful in disease treatment and management?
• Pulmonary complications of arthritis: What are they and how to treat?
• Bone marrow transplants for the treatment of severe scleroderma: What have we learned?
• Cardiovascular risks in inflammatory arthritis: Risk assessment and management in daily practice
• Ultrasound in the management of inflammatory arthritis: Consensus or debate?
• Who to choose for the management of arthritis: Rheumatologists or orthopaedic surgeons?
• Randomized controlled trials: Design and analysis
• Systemic lupus erythematosus: Biologic or non-biologic treatment?
• Headache for rheumatologists: Pain and central sensitization syndrome
• Use of biologics for rheumatoid arthritis treatment in countries without reimbursement: How do we address the needs of those patients?
• Biosimilars: Old and new. What have we learned so far?
• Which biologics are safe for tuberculosis and/or hepatitis C?
• Biologics for the treatment of symptomatic osteoarthritis: Safer and more effective than NSAIDs and SySADOAS?
• Tanezumab and osteoarthritis: Facts and rebirth
• Intraarticular injections of corticosteroids, platelet rich plasma, and stem cells for osteoarthritis treatment: What to tell patients?
• Metabolomics and osteoarthritis
• Osteoporosis management for the rheumatologist: Western vs. Asian countries

Boulos Haraoui, Canada

Tore K. Kvien, Norway

Johanne Martel-Pelletier, Canada

Jean-Pierre Pelletier, Canada

Lee S. Simon, USA

USD

Group registrations not allowed

Accompanying persons not allowed

We don’t accept Online Abstracts

Submission Info

Abstract submission opens 2019-02-09

Abstract submission deadline 2019-05-14

• Abstracts can be submitted online only. Abstracts submitted via fax or email will not be accepted.
• All abstracts must be submitted and presented in English. 
• The abstract title is limited to 27 words and should be in CAPS.
• The abstract body may not be longer than 350 words.
• Authors are limited to 15 per abstract.
• Abstracts may include a maximum of one picture or graph or one graph per abstract -- in JPEG format only.
• The text must be formatted in Ariel font size 10. Only the title, abbreviations and acronyms should be in ALL CAPS.
• Abbreviations should be defined.
  
• Please write concisely and clearly and structure your abstract with the headings:
  Problem statement 
  Methods
  Results
  Conclusion
  
• Please ensure that your abstract does not contain spelling, grammar or scientific errors, as it will be reproduced exactly as submitted. No proofreading will be done. Linguistic accuracy is the responsibility of the submitter.
• Abstract submissions that do not meet the above noted guidelines may be rejected without review.
  
• Please include Disclosure of Interest, if any, at the end of the abstract body.
  
• The Organizing Committee may request additional information about abstracts.

Who is eligible to enter?

Physicians, scientists & researchers born in 1985 or after.

What is this competition all about?

The Scientific Committee of the 7th World Congress on Controversies, Debates & Consensus in Bone, Muscle & Joint Diseases invites young scientists and researchers to submit their work and to join the Young Scientist Award competition.

The winner(s) will receive a cash prize, and the abstract(s) will be presented as oral presentations.

Wow! How do I enter?

It’s very simple.

1. Submit your abstract via the Congress website no later than May 14, 2019. (http://bmjd-congress.org/call-for-abstracts/)

2. Register and pay registration fees.

3. Include your date of birth during the registration process.

Great! So what are the guidelines for submitting?

• Submitters must be born in 1985 or after.
• Submitters must be the first author of the abstract.
• Attendance at the BMJD Congress by the winner is mandatory in order to receive and collect the award.
• Winner(s) who cancel for any reason will not be entitled to collect their award.

Note that abstracts sent by email or fax will automatically be rejected.